Status report for phase 2 study
SpectraCure has conducted a Phase 1 clinical trial for the treatment of patients with recurrent prostate cancer with the company's technology for photodynamic therapy (PDT). As previously announced, at the end of 2018, the company entered the final stage of planning for a subsequent phase 2 study. In early 2019, SpectraCure renewed certain contracts and […]
Final preparation for Phase 2 – SpectraCure extends contract with hospital in London
Prior to the upcoming Phase 2 study, SpectraCure has today extended the agreement with University College London Hospital (UCL) for two years. The agreement is intended to cover the entire phase 2 for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. The purpose of the Phase 2 study is […]
More results from Phase 1 study
Results of the evaluation of PSA values have been reported in the clinical phase 1 study that SpectraCure is currently running for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. PSA (prostate-specific antigen) is a blood marker that can indicate the presence of a tumour in the prostate. The […]
Results from clinical study for patient 9 and 10
In SpectraCure’s Phase 1 study for treatment of patients with recurrent prostate cancer, preliminary results have been reported for the most recently treated patients. The treatment method, called photodynamic therapy (PDT), means that the patient is given a light-activated drug that accumulates in the tumour. When the cancerous tissue is illuminated using SpectraCure’s IDOSE technique, […]
SpectraCure receives prestigious grant from the Eurostars program
SpectraCure has been awarded an R&D grant of approximately SEK 5 million through the EU Eurostars program, to develop an advanced image management system to be used together with the company's IDOSE technology. The development project will be carried out together with the German company MedCom GmbH, which will also receive a grant. SpectraCure has […]
SpectraCure one step closer to Phase 2 after successful treatment effect in recent patients
SpectraCure will, as previously announced, enter a Phase 2 clinical trial in early 2019. This is a result of successful treatment effects seen in the most recently treated patients. A clear therapeutic effect is seen in these patients, with intended changes seen in the tumor region thanks to SpectraCure’s method based on photodynamic tumor treatment […]
Continued patient treatments in clinical trial
A further two patients were treated 3rd May in SpectraCure's clinical trial for treatment of recurrent prostate cancer at the Princess Margaret Cancer Centre in Toronto. The treatments were done with the method based on photodynamic therapy (PDT) developed by SpectraCure. As before, the treatments were performed by a team led by Drs Neil Fleshner […]
Agreement signed with the University of Pennsylvania Hospital for Clinical Study on Prostate Cancer Treatment
SpectraCure has signed an agreement with the University of Pennsylvania Hospital ("Penn Hospital") in Philadelphia, USA. The agreement concerns clinical studies for treatment of patients with recurrent prostate cancer with the company's photodynamic tumor therapy technique (PDT). Penn Hospital will be involved in the Phase 1 study that is also conducted at the Princess Margaret Cancer Center […]
The ethics committee in London gives approval to start clinical study
As previously announced, SpectraCure has received approval from Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to conduct parts of the ongoing Phase 1 clinical trial for the treatment of prostate cancer in London. Now, also the regional ethics committee in London has approved the study protocol. This means that all formal requirements […]
Additional results from clinical phase 1 study
SpectraCure is conducting a Phase 1 clinical trial for the treatment of patients with relapse of prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the fourth patient was treated on February 22nd at the Princess Margaret Cancer Centre in Toronto. During the follow-up after treatment, patients' PSA values are monitored on […]
